BioPharmSignal logoBioPharmSignal

Biotech News

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

Xeris Pharmaceuticals (XERS)Xeris PharmaceuticalsFDA / regulatory

Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030 The Company expects XP-8121 peak net revenue potential of $1 to $3 billion CHICAGO --(BUSINESS WIRE)--Sep.

Related news

XERSXeris Pharmaceuticals2026-08-26 11:30 EST

Xeris Announces Details for XP-8121 Program Overview Webinar

GANXGain Therapeutics2026-06-29 20:05 EST

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

XENEXenon2026-09-17 20:01 EST

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

TEVATeva Pharmaceutical Industries2026-08-28 10:17 EST

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

XERSXeris Pharmaceuticals2026-06-11 20:39 EST

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®

ACIUAC Immune2026-08-11 11:00 EST

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

PRAXPraxis Precision Medicines2026-06-29 20:30 EST

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

PRAXPraxis Precision Medicines2026-06-22 12:00 EST

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

BCLIBrainstorm Cell Therapeutics Inc.2026-07-28 12:00 EST

BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman

View all latest news

Xeris Pharmaceuticals

Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability. Endocrine Products Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome....

Recent company news

XERSXeris Pharmaceuticals2026-09-09 12:30 EST

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

XERSXeris Pharmaceuticals2026-08-26 11:30 EST

Xeris Announces Details for XP-8121 Program Overview Webinar

XERSXeris Pharmaceuticals2026-08-06 11:00 EST

Xeris Biopharma Reports Second Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-07-23 11:30 EST

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

XERSXeris Pharmaceuticals2026-07-02 20:05 EST

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stock data

Close
8.16 USD
Market cap
1.04B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States